Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1750MR)

This product GTTS-WQ1750MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1750MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6110MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ9084MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ4223MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ15520MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ9104MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ12697MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ7378MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ8291MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HM-12525A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW